Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant

Executive Summary

Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.

Advertisement

Related Content

Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis
Kyprolis ENDEAVOR data signal a changing of the guard for multiple myeloma treatment
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel